Defective homologous recombination in human cancers

A. Cerbinskaite, A. Mukhopadhyay, E. R. Plummer, N. J. Curtin, R. J. Edmondson

    Research output: Contribution to journalArticlepeer-review


    Homologous recombination (HR) is a process by which DNA double strand breaks are repaired through the alignment of homologous sequences of DNA. Interest continues to increase in HR pathway function due to the development of new therapeutic agents which selectively exploit DNA damage repair pathways. Currently the most promising of these new agents are inhibitors of poly(ADP ribose) polymerase (PARP). The response of cancers known to be deficient in HR, due to BRCA1 or 2 mutations has been demonstrated, and a wider use of PARP inhibitors in cancers with mutations of other HR pathway genes has been suggested. With ongoing clinical studies into the use of PARP inhibitors, further understanding of the HR pathway, to allow patient selection by cancer biology, is now essential. Numerous studies have investigated individual aberrations of genes involved in the HR pathway. Here we collate this evidence to give an overview of the role of the HR pathway in human cancer. © 2011 Elsevier Ltd.
    Original languageEnglish
    Pages (from-to)89-100
    Number of pages11
    JournalCancer Treatment Reviews
    Issue number2
    Publication statusPublished - Apr 2012


    • ATM
    • ATR
    • BRCA
    • DNA repair
    • FANC
    • Homologous recombination
    • MRE11
    • NSB1
    • RAD50
    • RAD51


    Dive into the research topics of 'Defective homologous recombination in human cancers'. Together they form a unique fingerprint.

    Cite this